Xencor Inc (XNCR) 18.18 $XNCR
Can The Uptrend Continue for Xencor (XNCR)?
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 3:17AM CDT
Investors certainly have to be happy with Xencor Inc (XNCR) and its short term performance
XNCR: 18.18 (-0.44)
5 Best-Performing Biotech Stocks of June
Arpita Dutt - Zacks Investment Research - Tue Jul 05, 2:28PM CDT
These 5 biotech stocks managed to beat the downward trend and shot up more than 20% in the month of Jun 2016.
XBIT: 19.40 (+3.62), OPXA: 4.40 (+0.14), AVXL: 7.89 (+0.31), TTHI: 1.58 (+0.03), XNCR: 18.18 (-0.44)
Can Xencor (XNCR) Run Higher on Strong Earnings Estimate Revisions?
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 7:45AM CDT
Xencor, Inc. (XNCR) has decent short-term momentum and it is also seeing solid activity on the earnings estimate revision front as well
XNCR: 18.18 (-0.44)
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 5:20PM CDT
Shares of Xencor, Inc. (XNCR) rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Novartis AG (NVS).
PFE: 36.31 (+0.19), AMGN: 161.18 (+0.08), XNCR: 18.18 (-0.44), NVS: 82.58 (+0.45)
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 97.63 (+2.80), GILD: 87.08 (+0.53), MDCO: 36.57 (+1.67), ALXN: 126.44 (+2.02), RGLS: 3.51 (+0.01), ABBV: 64.63 (+0.47), XNCR: 18.18 (-0.44)
Coverage of Top Gainers ReachLocal, Xencor, and Twilio
ACCESSWIRE - Wed Jun 29, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces its coverage of market signals with highlight on these Top Gainers from Monday's session: ReachLocal Inc. (NASDAQ: RLOC), Xencor Inc. (NASDAQ: XNCR), and Twilio Inc. (NYSE:TWLO). Register with us now for your free membership and get more on our signal alert and insight for ReachLocal at:
KO: 45.73 (+0.35), FB: 118.11 (+0.87), GCI: 13.90 (+0.09), JWN: 40.53 (+0.21), TWLO: 37.78 (+2.24), RLOC: 4.56 (unch), XNCR: 18.18 (-0.44)
Hess rises and ReachLocal skyrockets; Regulus, Dow fall
AP - Tue Jun 28, 3:34PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:
MCK: 193.30 (+0.51), CCL: 45.42 (+0.90), HES: 56.55 (-0.26), ED: 80.35 (-0.03), DD: 64.36 (+0.67), XNCR: 18.18 (-0.44), DOW: 50.03 (+0.63)
Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676
PR Newswire - Tue Jun 28, 12:15AM CDT
Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb®14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb®13676 also expected to begin clinical development for B-cell malignancies in 2016.
XNCR: 18.18 (-0.44), NVS: 82.58 (+0.45)
Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference
PR Newswire - Wed May 18, 11:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses greater-than or equal to 2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. Data are being presented Wednesday May 18, 2016 at 9:00 a.m. PT at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, CA (A6476: Poster Board Number 407).
XNCR: 18.18 (-0.44)
Xencor to Present at Upcoming Investor Conferences
PR Newswire - Tue May 17, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
XNCR: 18.18 (-0.44)
Xencor reports 1Q loss
Automated Insights - Mon May 02, 3:57PM CDT
MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $6.4 million in its first quarter.
XNCR: 18.18 (-0.44)
Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016
PR Newswire - Mon Apr 25, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2016 financial results after the market closes on Monday, May 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 18.18 (-0.44)
Xencor (XNCR) Catches Eye: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 7:15AM CST
Xencor, Inc. (XNCR) shares rose almost 7% in the last trading session.
EARS: 4.06 (-0.03), XNCR: 18.18 (-0.44)
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 07, 3:02PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a review of 2015 and recent business and clinical highlights.
AMGN: 161.18 (+0.08), XNCR: 18.18 (-0.44)
Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
PR Newswire - Mon Mar 07, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
XNCR: 18.18 (-0.44)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 7.17 (+0.04), XNCR: 18.18 (-0.44), PDLI: 3.29 (+0.01)
Xencor to Present at Two Upcoming Conferences in February
PR Newswire - Wed Feb 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:
XNCR: 18.18 (-0.44)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 42.79 (+1.34), PFE: 36.31 (+0.19), AZN: 30.15 (+0.04), IMGN: 3.05 (-0.15), AMGN: 161.18 (+0.08), BMY: 75.72 (+0.44), XNCR: 18.18 (-0.44), DYAX: 38.04 (-0.37)
Emergent Technologies Portfolio Company Enters into License Agreement with Xencor
BusinessWire - Tue Jan 12, 5:00AM CST
Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
XNCR: 18.18 (-0.44)
Xencor Announces Change to Board of Directors
PR Newswire - Mon Jan 11, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that John Stafford, III has notified the company of his decision to resign effective January 5, 2016 from the Board of Directors after 18 years of service to the company.
XNCR: 18.18 (-0.44)
Can The Uptrend Continue for Xencor (XNCR)?
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 3:17AM CDT
Investors certainly have to be happy with Xencor Inc (XNCR) and its short term performance
XNCR: 18.18 (-0.44)
5 Best-Performing Biotech Stocks of June
Arpita Dutt - Zacks Investment Research - Tue Jul 05, 2:28PM CDT
These 5 biotech stocks managed to beat the downward trend and shot up more than 20% in the month of Jun 2016.
XBIT: 19.40 (+3.62), OPXA: 4.40 (+0.14), AVXL: 7.89 (+0.31), TTHI: 1.58 (+0.03), XNCR: 18.18 (-0.44)
Can Xencor (XNCR) Run Higher on Strong Earnings Estimate Revisions?
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 7:45AM CDT
Xencor, Inc. (XNCR) has decent short-term momentum and it is also seeing solid activity on the earnings estimate revision front as well
XNCR: 18.18 (-0.44)
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 5:20PM CDT
Shares of Xencor, Inc. (XNCR) rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Novartis AG (NVS).
PFE: 36.31 (+0.19), AMGN: 161.18 (+0.08), XNCR: 18.18 (-0.44), NVS: 82.58 (+0.45)
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 97.63 (+2.80), GILD: 87.08 (+0.53), MDCO: 36.57 (+1.67), ALXN: 126.44 (+2.02), RGLS: 3.51 (+0.01), ABBV: 64.63 (+0.47), XNCR: 18.18 (-0.44)
Coverage of Top Gainers ReachLocal, Xencor, and Twilio
ACCESSWIRE - Wed Jun 29, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces its coverage of market signals with highlight on these Top Gainers from Monday's session: ReachLocal Inc. (NASDAQ: RLOC), Xencor Inc. (NASDAQ: XNCR), and Twilio Inc. (NYSE:TWLO). Register with us now for your free membership and get more on our signal alert and insight for ReachLocal at:
KO: 45.73 (+0.35), FB: 118.11 (+0.87), GCI: 13.90 (+0.09), JWN: 40.53 (+0.21), TWLO: 37.78 (+2.24), RLOC: 4.56 (unch), XNCR: 18.18 (-0.44)
Hess rises and ReachLocal skyrockets; Regulus, Dow fall
AP - Tue Jun 28, 3:34PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:
MCK: 193.30 (+0.51), CCL: 45.42 (+0.90), HES: 56.55 (-0.26), ED: 80.35 (-0.03), DD: 64.36 (+0.67), XNCR: 18.18 (-0.44), DOW: 50.03 (+0.63)
Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676
PR Newswire - Tue Jun 28, 12:15AM CDT
Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb®14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb®13676 also expected to begin clinical development for B-cell malignancies in 2016.
XNCR: 18.18 (-0.44), NVS: 82.58 (+0.45)
Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference
PR Newswire - Wed May 18, 11:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses greater-than or equal to 2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. Data are being presented Wednesday May 18, 2016 at 9:00 a.m. PT at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, CA (A6476: Poster Board Number 407).
XNCR: 18.18 (-0.44)
Xencor to Present at Upcoming Investor Conferences
PR Newswire - Tue May 17, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
XNCR: 18.18 (-0.44)
Xencor reports 1Q loss
Automated Insights - Mon May 02, 3:57PM CDT
MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $6.4 million in its first quarter.
XNCR: 18.18 (-0.44)
Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016
PR Newswire - Mon Apr 25, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2016 financial results after the market closes on Monday, May 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 18.18 (-0.44)
Xencor (XNCR) Catches Eye: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 7:15AM CST
Xencor, Inc. (XNCR) shares rose almost 7% in the last trading session.
EARS: 4.06 (-0.03), XNCR: 18.18 (-0.44)
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 07, 3:02PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a review of 2015 and recent business and clinical highlights.
AMGN: 161.18 (+0.08), XNCR: 18.18 (-0.44)
Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
PR Newswire - Mon Mar 07, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
XNCR: 18.18 (-0.44)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 7.17 (+0.04), XNCR: 18.18 (-0.44), PDLI: 3.29 (+0.01)
Xencor to Present at Two Upcoming Conferences in February
PR Newswire - Wed Feb 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:
XNCR: 18.18 (-0.44)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 42.79 (+1.34), PFE: 36.31 (+0.19), AZN: 30.15 (+0.04), IMGN: 3.05 (-0.15), AMGN: 161.18 (+0.08), BMY: 75.72 (+0.44), XNCR: 18.18 (-0.44), DYAX: 38.04 (-0.37)
Emergent Technologies Portfolio Company Enters into License Agreement with Xencor
BusinessWire - Tue Jan 12, 5:00AM CST
Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
XNCR: 18.18 (-0.44)
Xencor Announces Change to Board of Directors
PR Newswire - Mon Jan 11, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that John Stafford, III has notified the company of his decision to resign effective January 5, 2016 from the Board of Directors after 18 years of service to the company.
XNCR: 18.18 (-0.44)
